worst crisis in living memory, page-19

Muzza

You missed out the fact that the LANI license is being negotiated right now, at the best possible time - whilst we are on the brink of a pandemic in the UK for starters - and this also adds weight to Biota's attempts to snare a large US govt grant to cover the majority of their Phase III Lani clinical trials.

This all allows Biota to maximise the upfront payment from the prospective licensee...

...big $$$ heading Biota's way - enough to more than likely double their market cap within the next 6 months.

Now, this is the PC and co. last hurrah to make the most of the opportunity. The downside is their track record, but surely this time, the upside will outweigh the downside.

Long term holders will realise their original dreams.

Medium term holders will regain their lost ground over the last year or so.

Short term holders will take some handsome profits.